Filter News
Area of Research
- (-) Fusion and Fission (4)
- (-) Nuclear Science and Technology (10)
- Advanced Manufacturing (1)
- Biology and Environment (30)
- Clean Energy (78)
- Climate and Environmental Systems (1)
- Computational Biology (1)
- Computational Engineering (2)
- Computer Science (2)
- Electricity and Smart Grid (1)
- Fusion Energy (7)
- Isotopes (3)
- Materials (24)
- Materials for Computing (5)
- Mathematics (1)
- National Security (8)
- Neutron Science (10)
- Nuclear Systems Modeling, Simulation and Validation (1)
- Quantum information Science (1)
- Sensors and Controls (1)
- Supercomputing (21)
- Transportation Systems (2)
News Topics
- (-) Advanced Reactors (10)
- (-) Biomedical (2)
- (-) Grid (1)
- (-) Molten Salt (3)
- (-) Transportation (1)
- 3-D Printing/Advanced Manufacturing (2)
- Bioenergy (1)
- Biology (1)
- Chemical Sciences (2)
- Computer Science (2)
- Critical Materials (1)
- Decarbonization (2)
- Energy Storage (2)
- Fossil Energy (1)
- Fusion (12)
- Isotopes (3)
- ITER (4)
- Materials (1)
- Materials Science (5)
- Microscopy (1)
- Nanotechnology (1)
- Neutron Science (4)
- Nuclear Energy (26)
- Partnerships (2)
- Physics (1)
- Security (1)
- Simulation (1)
- Space Exploration (5)
- Sustainable Energy (2)
- Transformational Challenge Reactor (1)
Media Contacts
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
Experts focused on the future of nuclear technology will gather at Oak Ridge National Laboratory for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.